Searched for
DIABETIC DYSLIPIDEMIA
These large-, mid- and small-cap stocks can give more than 25% return in 1 year, according to analysts- For both the compulsive trader and careful investor: 25 stocks to watch if risk appetite returns; some with upside potential, some not
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 29%
- Zydus, Lupin sign pact to co-market weight-loss Semaglutide injection in IndiaZydus Lifesciences and Lupin have joined forces to bring Semaglutide Injection to India. This medication helps manage type 2 diabetes and a...17 Mar, 2026, 12.22 PM IST
- Cholesterol test at age 18, Non-fasting measurement: Cardiologists Suggest New Guidelines on how to prevent heart attacksThe Cardiologist Society of India (CSI) now recommends lipid profiles starting at age 18, with non-fasting measurements as the new norm. Th...06 Jul, 2024, 11.51 AM IST
- Apollo Hospitals launches AI-driven personalised preventive health profileApollo's 'ProHealth' program is backed by a predictive algorithm that captures one’s health status, predicts potential health risks and ind...06 Apr, 2023, 09.51 PM IST
- Zydus Cadila receives DCGI nod for NAFLD drug Saroglitazar Mg in IndiaNon-Alcoholic Fatty Liver Disease (NAFLD) is a progressive disease of the liver, which starts with fat accumulation in the liver in patient...30 Dec, 2020, 11.10 AM IST
- Zydus Cadila gets DCGI nod for world's first drug to treat liver diseaseThe Ahmedabad-based company said the approved product is the first ever drug anywhere in the world for treatment of Non-Cirrhotic Non-Alcoh...05 Mar, 2020, 06.50 PM IST
- Zydus Cadila files NDA for Saroglitazar MagnesiumNASH is a progressive disease of the liver and a significant unmet medical need. There are currently no treatments available for the treatm...05 Dec, 2019, 01.10 PM IST
- Zydus gets regulatory nod to market Lipaglyn in MexicoThe company has been granted marketing approval from the Mexican regulatory authority COFEPRIS to commercialise Lipaglyn in Mexico, Zydus s...10 Nov, 2017, 02.18 PM IST
- US FDA pulls up Cadila for misbranding drugThe company has been researching on the drug to treat fatty liver disease or non-alcoholic steatohepatitis apart from diabetic dyslipidemia.29 Dec, 2016, 12.15 AM IST
- Cadila Healthcare misbranded Saroglitazar, says US FDAIn a December 21 letter to the company, the US FDA has said the “broad statements” made by the company as the “world’s first” is misleading...28 Dec, 2016, 11.46 AM IST
- Zydus launches Tenglyn tablets in Indian marketDrug firm Zydus Cadila has launched its generic Tenglyn tablets belonging to new class of oral anti-diabetic treatment drugs, Gliptins, in ...20 Nov, 2015, 07.30 PM IST
- Zydus gets USFDA nod for clinical trials of Sarolitazar"USFDA has endorsed company's plan to initiate a phase II clinical trial of Saroglitazar in patients with severe hypertriglyceridemia," Zyd...18 Nov, 2015, 01.43 PM IST
- Zydus Cadila Q2 net profit up by 94%Besides Lipaglyn, the group launched 19 new products, including line extensions in India of which, four were first in India.31 Oct, 2013, 03.13 PM IST
- Zydus to invest Rs 100 crore in Vadodara unit, expand hospital businessZydus Hospitals & Healthcare Research recently started its first hospital operations at Anand, better known as Amul's hometown.19 Aug, 2013, 01.18 PM IST
- Zydus to launch first new chemical entity by desi companyCadila Healthcare on Wednesday said that its new chemical entity (NCE), Lipaglyn , has been approved by the Drug Controller General of Indi...06 Jun, 2013, 06.59 AM IST
- Zydus Cadila gets DCGI nod for launch of its NCE for diabetesCadila Healthcare today said Indian drug regulator has approved its new chemical entity, Lipaglyn to be used for treating a type of diabetes05 Jun, 2013, 02.40 PM IST
- Zydus Cadila to launch molecule for diabetesPharma major Cadila Healthcare may soon become one of a handful of Indian companies to launch an indigenously developed molecule.19 Mar, 2013, 10.59 AM IST
- Cadila files new drug application; share up nearly 1%Cadila Healthcare has filed an investigational new drug application for conducting clinical trials for molecular entity - ZYH7, to treat dy...30 Aug, 2007, 11.11 AM IST
Load More
